STEPSNCT07208097
Stereotactic Thrombolysis With Tenecteplase for Supratentorial Intracerebral Hemorrhage
At risk: Primary endpoint(s) modified.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary endpoint(s) modified Show 4 more changesShow less
- Eligibility criteria expanded, about 27 words
- Trial sites expanded: 2 → 51 locations
- Secondary endpoints: 11 to 10
- Study description expanded, about 2 words
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 2
- Start date changed from estimate of Oct 15, 2025 to Oct 25, 2025
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Functional Outcomes Measured Via Modified Rankin Score (mRS) of ≤ 3
Timeframe: 180 days post-randomization
Secondary (10)
Functional Outcomes Measured Via Modified Ordinal Rankin Score (mRS)
Functional Outcomes Measured Via Utility Weighted Modified Rankin Score (mRS)
Functional Outcomes Measured Via Modified Rankin Score (mRS) of ≤ 2
Functional Outcomes Measured Via Modified Rankin Score (mRS) of ≤ 1
Functional Outcomes Measured Via eGOS of 4-8
Show 5 moreShow less
Mortality
Health-related quality of daily life
Early neurological improvement
Residual hematoma volume
Clot removal rate
Arms and interventions
MIS+TNKExperimental
In this group, patients receive standard medical treatment plus mininally invasive stereotactic catheter placement followed by hematoma liquefaction and drainage using tenecteplase (TNK). The single dose of tenecteplase is 0.5mg.
Standard medical treatmentNo intervention
Patients randomized to the control group will receive standard medical management according to the 2022 AHA/ASA Guideline for the Management of Spontaneous Intracerebral Hemorrhage.
Procedures: Stereotactic thrombolysis with Tenecteplase
Sites
51 sites in 1 country